Cat. No.: HY-101663

Ruzasvir

Name: Ruzasvir
Brand: MedChemExpress
SKU: HY-101663
Price: 200.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: MK-8408)

Avis client

Based on 1 Customer Validation

Ruzasvir (MK-8408) is a potent, pan-genotype HCV NS5A inhibitor that blocks RNA synthesis, replication, and assembly. Ruzasvir produces additive to synergistic antiviral effects with Bemnifosbuvir (HY-137958A), Grazoprevir (HY-15298), or Uprifosbuvir (HY-103487) analogs, with no antagonism. Ruzasvir can be used for research on HCV infection.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté : 98.15%
CAS No.: 1613081-64-3
Formule: C₄₉H₅₅FN₁₀O₇S
Masse moléculaire:947.09

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Ruzasvir Chemical Structure

CAS No.: 1613081-64-3

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- Parmacokinetics
Chemical Information
Solvant et solubilité
- In Vitro
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis :

Cellular Effect

Cell Line	Type	Value	Description	References
Huh-7	EC90	0.003 nM	Inhibition of HCV GT1a replicon replication in Huh-7 derived cells assessed by decreased luciferase signal. Inhibition of HCV GT1a replicon replication in Huh-7 derived cells assessed by decreased luciferase signal.	27808515
Huh-7	EC90	0.016 nM	Inhibition of HCV GT1a L31V replicon replication in Huh-7 derived cells assessed by decreased luciferase signal. Inhibition of HCV GT1a L31V replicon replication in Huh-7 derived cells assessed by decreased luciferase signal.	27808515
Huh-7	EC90	0.067 nM	Inhibition of HCV GT1a Y93H replicon replication in Huh-7 derived cells assessed by decreased luciferase signal. Inhibition of HCV GT1a Y93H replicon replication in Huh-7 derived cells assessed by decreased luciferase signal.	27808515
Huh-7	EC90	0.036 nM	Inhibition of HCV GT2b(31M) replicon replication in Huh-7 derived cells assessed by decreased luciferase signal. Inhibition of HCV GT2b(31M) replicon replication in Huh-7 derived cells assessed by decreased luciferase signal.	27808515
Huh-7	EC90	0.007 nM	Inhibition of HCV GT3a replicon replication in Huh-7 derived cells assessed by decreased luciferase signal. Inhibition of HCV GT3a replicon replication in Huh-7 derived cells assessed by decreased luciferase signal.	27808515
Huh-7	EC90	0.009 nM	Inhibition of HCV NS5A Y93H variant replicon replication in Huh-7 derived cells assessed by decreased luciferase signal. Inhibition of HCV NS5A Y93H variant replicon replication in Huh-7 derived cells assessed by decreased luciferase signal.	27808515
Huh-7	EC90	0.011 nM	Inhibition of HCV NS5A Q30R variant replicon replication in Huh-7 derived cells assessed by decreased luciferase signal. Inhibition of HCV NS5A Q30R variant replicon replication in Huh-7 derived cells assessed by decreased luciferase signal.	27808515
Huh-7	EC90	0.002 nM	Inhibition of HCV NS5A Y93C variant replicon replication in Huh-7 derived cells assessed by decreased luciferase signal. Inhibition of HCV NS5A Y93C variant replicon replication in Huh-7 derived cells assessed by decreased luciferase signal.	27808515
Huh-7	EC90	0.001 nM	Inhibition of HCV GT2a replicon replication in Huh-7 derived cells assessed by decreased luciferase signal. Inhibition of HCV GT2a replicon replication in Huh-7 derived cells assessed by decreased luciferase signal.	27808515
Huh-7	EC90	0.006 nM	Inhibition of HCV GT3a replicon replication in Huh-7 derived cells assessed by decreased luciferase signal. Inhibition of HCV GT3a replicon replication in Huh-7 derived cells assessed by decreased luciferase signal.	27808515
Huh-7	EC90	0.027 nM	Inhibition of HCV GT6d replicon replication in Huh-7 derived cells assessed by decreased luciferase signal. Inhibition of HCV GT6d replicon replication in Huh-7 derived cells assessed by decreased luciferase signal.	27808515
Huh-7	EC50	1 pM	Antiviral activity against HCV genotype 1a in human Huh-7 replicon cells assessed as EC50 by replicon assay. Antiviral activity against HCV genotype 1a in human Huh-7 replicon cells assessed as EC50 by replicon assay.	40054502
Huh-7	EC50	2 pM	Antiviral activity against HCV genotype 1b in human Huh-7 replicon cells assessed as EC50 by replicon assay. Antiviral activity against HCV genotype 1b in human Huh-7 replicon cells assessed as EC50 by replicon assay.	40054502
Huh-7	EC50	4 pM	Antiviral activity against HCV genotype 2b in human Huh-7 replicon cells assessed as EC50 by replicon assay. Antiviral activity against HCV genotype 2b in human Huh-7 replicon cells assessed as EC50 by replicon assay.	40054502
Huh-7.5	EC50	0.010 nM	Antiviral activity against transient HCV GT1a isolate NC004102 (H77) replicon in Huh7.5 cells assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient HCV GT1a isolate NC004102 (H77) replicon in Huh7.5 cells assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.003 nM	Antiviral activity against transient HCV GT1a isolate EU781816 replicon in Huh7.5 cells assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient HCV GT1a isolate EU781816 replicon in Huh7.5 cells assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.002 nM	Antiviral activity against transient HCV GT1a isolate AY956464 replicon in Huh7.5 cells assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient HCV GT1a isolate AY956464 replicon in Huh7.5 cells assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.005 nM	Antiviral activity against transient HCV GT1a isolate AY956463 replicon in Huh7.5 cells assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient HCV GT1a isolate AY956463 replicon in Huh7.5 cells assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.007 nM	Antiviral activity against transient HCV GT1b isolate AJ238799 (Con1) replicon in Huh7.5 cells assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient HCV GT1b isolate AJ238799 (Con1) replicon in Huh7.5 cells assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.006 nM	Antiviral activity against transient HCV GT1b isolate AB049087 replicon in Huh7.5 cells assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient HCV GT1b isolate AB049087 replicon in Huh7.5 cells assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.004 nM	Antiviral activity against transient HCV GT1b isolate EF407458 replicon in Huh7.5 cells assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient HCV GT1b isolate EF407458 replicon in Huh7.5 cells assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.014 nM	Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with WT NS5A assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with WT NS5A assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.016 nM	Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A M28A substitution assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A M28A substitution assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.015 nM	Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Q30E substitution assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Q30E substitution assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.013 nM	Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Q30H substitution assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Q30H substitution assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.019 nM	Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Q30K substitution assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Q30K substitution assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.011 nM	Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Q30L substitution assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Q30L substitution assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.012 nM	Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Q30N substitution assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Q30N substitution assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.017 nM	Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Q30R substitution assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Q30R substitution assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.018 nM	Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A L31M substitution assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A L31M substitution assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.076 nM	Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A L31V substitution assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A L31V substitution assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.026 nM	Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A H58R substitution assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A H58R substitution assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.038 nM	Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Y93H substitution assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Y93H substitution assessed by Gaussia luciferase after 72 hrs incubation.	30150466
Huh-7.5	EC50	0.090 nM	Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Y93N substitution assessed by Gaussia luciferase after 72 hrs incubation. Antiviral activity against transient full-length HCV GT1a H77 replicon in Huh7.5 cells with NS5A Y93N substitution assessed by Gaussia luciferase after 72 hrs incubation.	30150466

In Vitro

Viral InfectionOthers

Viral Infection

Ruzasvir inhibits HCV replicon replication in Huh-7-derived cells, with EC₉₀ = 0.003 nM against GT1a, and maintains subnanomolar to low nanomolar EC₉₀ values across GT1-GT6 and key GT1 variants^[3].
Ruzasvir is a highly potent HCV NS5A inhibitor, with EC₅₀ values of 1-4 pM against the tested HCV genotypes in Huh-7 replicons and an EC₅₀ of 5.0 pM against HCV GT1b in Huh-luc/neo-ET reporter replicon cells^[5].
Ruzasvir inhibits HCV RNA replication of HCV GT1-GT7 in Huh7/Huh7.5 stable replicon cells, with EC₅₀ of 0.0007-0.004 nM, and GT1a H77 maintains an EC₅₀ of 0.010 nM in 40% normal serum^[6].
Ruzasvir (0.01-20× EC₉₀; 72 h) in combination with Grazoprevir or Uprifosbuvir analogs produces additive to synergistic inhibition of GT1a or GT3 replicon RNA, without antagonism or cytotoxicity^[6].
Ruzasvir inhibits HCV replicon genotypes 1-6, with EC₉₀ = 0.003 nM against GT1a (H77) and maintains EC₉₀ = 0.067 nM against GT1a Y93H^[7].

Others

Ruzasvir (25 µM) shows no cytotoxicity in Huh7, HepG2, HEK293T, and Hep3B cells^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[6]

Cell Line:

GT1a and GT3 HCV replicon cells
Concentration:

0.01 to 20× EC₉₀ for each compound
Incubation Time:

72 h
Result:

Combined with grazoprevir in GT1a replicon cells: run 1 log volume 0/−0.68, additive; run 2 4.03/0, minor synergy; run 3 2.42/0, minor synergy.
Combined with uprifosbuvir analogue in GT3 replicon cells: run 1 41.01/0, strong synergy; run 2 14.71/−0.37, strong synergy; run 3 23.83/0, strong synergy.
No appreciable cytotoxicity was observed in either GT1a or GT3 replicon cells.

Related Protocols :

Research Protocol for Infectious Diseases

Parmacokinetics

Species	Dose	Route	AUC_0-t	F	AUC	T_1/2
Rat^[3]	10 mg/kg	p.o.	/	4 %	0.4 μM·h	/
Dog^[3]	5 mg/kg	p.o.	12.9 μM·h	22 %	/	/
Rhesus monkey^[3]	1 mg/kg	i.v.	/	/	/	10.2 h
Rhesus monkey^[3]	5 mg/kg	p.o.	3.9 μM·h	10 %	/	/

Chemical Information

CAS No. 1613081-64-3
Appearance Solid
Masse moléculaire 947.09
Formule C₄₉H₅₅FN₁₀O₇S
Color Light yellow to yellow
SMILES

FC1=C2C3=CC4=CC(C5=CN=C([C@H](CCC6)N6C([C@H](C(C)C)NC(OC)=O)=O)N5)=CC=C4N3[C@H](C7=CN=C(C8CC8)S7)OC2=CC(C9=CN=C([C@H](CCC%10)N%10C([C@H](C(C)C)NC(OC)=O)=O)N9)=C1
Synonyms

MK-8408
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (105.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.0559 mL

5.2793 mL

10.5587 mL

5 mM

0.2112 mL

1.0559 mL

2.1117 mL

10 mM

0.1056 mL

0.5279 mL

1.0559 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (276 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Gottwein JM, et al. Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1–7 and escape variants. Gastroenterology. 2018 Apr 1;154(5):1435-48.

[2]. Chan A, et al. Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs. 2017 Feb;77(2):131-144.

[3]. Tong L, et al. Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms. Journal of medicinal chemistry. 2017 Jan 12;60(1):290-306. [Content Brief]

[4]. Hu J, et al. Nucleotide analogue bemnifosbuvir inhibits hepatitis E virus replication in preclinical models. Gut. 2026 Mar 06.

[5]. Good SS, et al. Bemnifosbuvir and ruzasvir in combination exhibit potent synergistic antiviral activity in vitro while maintaining a favorable nonclinical safety profile in vivo. Antiviral research. 2025 May;237:106137.

[6]. Asante-Appiah E, et al. Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A. Antimicrobial agents and chemotherapy. 2018 Nov;62(11):e01280-18.

[7]. Tong L, et al. Discovery and Development of Ruzasvir: An Investigational Next Generation Pan-Genotype HCV Nonstructural Protein 5A (NS5A) Inhibitor for the Cure of Hepatitis C Virus Infections. InComplete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 1 2018 (pp. 115-149). American Chemical Society.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.0559 mL	5.2793 mL	10.5587 mL	26.3966 mL
	5 mM	0.2112 mL	1.0559 mL	2.1117 mL	5.2793 mL
	10 mM	0.1056 mL	0.5279 mL	1.0559 mL	2.6397 mL
	15 mM	0.0704 mL	0.3520 mL	0.7039 mL	1.7598 mL
	20 mM	0.0528 mL	0.2640 mL	0.5279 mL	1.3198 mL
	25 mM	0.0422 mL	0.2112 mL	0.4223 mL	1.0559 mL
	30 mM	0.0352 mL	0.1760 mL	0.3520 mL	0.8799 mL
	40 mM	0.0264 mL	0.1320 mL	0.2640 mL	0.6599 mL
	50 mM	0.0211 mL	0.1056 mL	0.2112 mL	0.5279 mL
	60 mM	0.0176 mL	0.0880 mL	0.1760 mL	0.4399 mL
	80 mM	0.0132 mL	0.0660 mL	0.1320 mL	0.3300 mL
	100 mM	0.0106 mL	0.0528 mL	0.1056 mL	0.2640 mL

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Ruzasvir

Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis